Continuing Bisphosphonate Treatment for Osteoporosis — For Whom and for How Long? — NEJM

Continuing Bisphosphonate Treatment for Osteoporosis — For Whom and for How Long? — NEJM

Bisphosphonates for Osteoporosis — Where Do We Go from Here? — NEJM

Bisphosphonates for Osteoporosis — Where Do We Go from Here? — NEJM

Emerging drugs for the management of cancer treatment induced bone loss; Expert Opinion on Emerging Drugs

Take home message: The very high rate of bone loss and the high incidence of fractures indicate that cancer patients at risk of CTIBL (cancer treatment induced bone loss) need to be carefully monitored and stratified for fracture risk. Although there is a strong evidence of efficacy in prevention of bone loss and reduction of fracture risk for many drugs approved for postmenopausal osteoporosis (PMO) and male osteoporosis, for CTIBL there are actually no drugs approved for this indication.